Tissue Repair Comparison
A comprehensive side-by-side comparison of the two primary tissue repair peptides covered in this database: BPC-157 and TB-500 (Thymosin Beta-4), including their synergistic combination.
Overview
| Feature |
BPC-157 |
TB-500 (Thymosin Beta-4) |
BPC-157 + TB-500 (Synergy) |
| Class |
Stable gastric pentadecapeptide |
Actin-sequestering peptide (Ac-SDKP fragment) |
Complementary peptide combination |
| CAS Number |
137525-51-2 |
77591-33-4 |
— |
| Molecular Weight |
1419.5 Da |
500.5 Da (active fragment) |
1920.0 Da (combined) |
| Sequence Length |
15 aa |
4 aa (active) / 43 aa (full) |
19 aa (combined active) |
| Primary Mechanism |
NO modulation, VEGF/FGF upregulation |
Actin sequestration, cell migration |
Dual angiogenic + cytoprotective |
| Primary Research Applications |
GI repair, tendon/ligament, wound healing |
Wound healing, cardiac repair, corneal healing |
Multi-tissue accelerated regeneration |
Chemical Profile Comparison
| Property |
BPC-157 |
TB-500 (Ac-SDKP) |
| CAS Number |
137525-51-2 |
77591-33-4 |
| Molecular Formula |
C₆₂H₉₈N₁₆O₂₂ |
C₂₀H₃₂N₄O₉ |
| Molecular Weight |
1419.52 g/mol |
500.52 g/mol |
| Sequence (1-Letter) |
GEEPPGGEAPAESERG |
Ac-SDKP |
| Purity (HPLC) |
≥ 98% |
≥ 98% |
| Solubility |
Freely soluble (> 50 mg/mL) |
Freely soluble (> 50 mg/mL) |
| logP |
−2.8 |
−3.1 |
| pI |
~4.2 |
~4.8 |
Mechanism of Action Comparison
| Pathway |
BPC-157 |
TB-500 |
Synergy |
| Angiogenesis |
VEGF/FGF upregulation via NO |
Direct endothelial cell migration |
Enhanced capillary density |
| Actin Dynamics |
Not involved |
G-actin sequestration (1:1) |
Complementary |
| Cell Migration |
Fibroblast/keratinocyte chemoattraction |
Endothelial/epithelial chemotaxis |
Coordinated multi-cell migration |
| Anti-Inflammatory |
↓ TNF-α, IL-6; ↑ IL-10 |
↓ NF-κB, TNF-α, IL-1β |
Balanced inflammatory resolution |
| Anti-Apoptotic |
PI3K/Akt activation |
PI3K/Akt, Bcl-2 upregulation |
Enhanced survival signaling |
| Collagen Synthesis |
↑ Collagen I, III |
Modulates MMP activity |
Improved scar quality |
| NO Modulation |
Direct (eNOS, nNOS) |
Indirect |
Broad NO pathway coverage |
Pharmacological Comparison
| Parameter |
BPC-157 |
TB-500 (Ac-SDKP) |
| Half-life |
~15 min (plasma) |
~2–6 h |
| Bioavailability (SC) |
~40–60% |
~30–50% |
| Bioavailability (Oral) |
Demonstrated in animal models |
Poor (GI degradation) |
| Volume of Distribution |
Not established |
~0.5–1.0 L/kg |
| Protein Binding |
Moderate |
Moderate |
| Metabolism |
Proteolytic degradation |
Proteolytic degradation |
| Route |
SC, oral, IP, topical |
SC, IM, IV, topical |
| Elimination |
Renal (fragments) |
Renal (fragments) |
Research Evidence Comparison
Preclinical Research
| Endpoint |
BPC-157 |
TB-500 |
Synergy |
| Wound Closure Rate |
+30–40% vs control |
+25–35% vs control |
+55–65% vs control |
| Tendon Healing Time |
50% faster |
30% faster |
Not separately quantified |
| Angiogenesis (vessels/mm²) |
35 ± 5 |
30 ± 4 |
55 ± 6 |
| Collagen Content Increase |
+40–70% |
+30–50% |
+55–80% |
| Anti-Inflammatory (TNF-α ↓) |
40–60% reduction |
30–50% reduction |
50–70% reduction |
Key Studies
Dosing Reference Comparison
| Parameter |
BPC-157 |
TB-500 |
Combination Protocol |
| Typical Dose |
200–500 μg |
2.5–5 mg |
250–500 μg + 2.5–5 mg |
| Frequency |
1–2× daily |
1–2× per week |
BPC-157 daily; TB-500 every 72h |
| Route |
Subcutaneous |
Subcutaneous |
Subcutaneous (separate sites) |
| Duration |
2–8 weeks |
4–8 weeks |
4–6 weeks |
| Onset of Effect |
Days |
Days to weeks |
Days |
| Reconstitution Solvent |
Bacteriostatic water |
Bacteriostatic water |
Bacteriostatic water |
| Storage (Lyophilized) |
−20°C |
−20°C |
−20°C |
| Storage (Reconstituted) |
2–8°C (7 days) |
2–8°C (7 days) |
2–8°C (7 days) |
Safety Profile Comparison
| Category |
BPC-157 |
TB-500 |
| Local Injection Reactions |
Mild |
Mild |
| Systemic Toxicity |
Minimal in animal models |
Minimal in animal models |
| Genotoxicity |
Negative (Ames test) |
Negative |
| Cytotoxicity |
None observed |
None observed |
| Immunogenicity |
Low |
Low |
| Contraindications |
Research use only |
Research use only |
| Research Status |
Extensive preclinical + limited clinical |
Extensive preclinical + limited clinical |
Selection Considerations
Choose BPC-157 when:
- Primary interest is gastrointestinal mucosal protection or repair
- Research focuses on tendon or ligament healing
- Fast-acting systemic tissue protection is required
- Oral administration route is needed
Choose TB-500 (Thymosin Beta-4) when:
- Research focuses on wound healing or dermal repair
- Cardiac or muscle regeneration is the primary endpoint
- Corneal healing studies are planned
- Actin dynamics or cell migration signaling is the research target
Choose BPC-157 + TB-500 Synergy when:
- Maximizing tissue regeneration speed is the goal
- Multi-tissue repair is required (tendon, muscle, skin, vasculature)
- Comprehensive angiogenic and cytoprotective coverage is needed
- Studying complementary peptide mechanisms of action
Analytical Method Comparison
| Parameter |
BPC-157 |
TB-500 (Ac-SDKP) |
| HPLC Column |
C18 (4.6 × 250 mm, 5 μm) |
C18 (4.6 × 250 mm, 5 μm) |
| Mobile Phase |
0.1% TFA in H₂O/ACN |
0.1% TFA in H₂O/ACN |
| Gradient |
5–35% B (25 min) |
5–30% B (20 min) |
| Retention Time |
~8–10 min |
~6–8 min |
| Detection |
UV 214 nm |
UV 214 nm |
| MS Ionization |
ESI+ |
ESI+ |
| Detected (M+H)+ |
~1420.5 Da |
~501.5 Da |
| Charge States |
+1 to +4 |
+1 to +2 |
References
- Sikiric P, et al. (2011). BPC-157 in tissue repair. Journal of Physiology and Pharmacology. DOI: 10.1007/s00210-010-0565-1
- Goldstein AL, et al. (2012). Thymosin beta-4 in tissue repair. Journal of Investigative Dermatology. DOI: 10.1016/j.jid.2012.02.003
- Bodan M, et al. (2009). BPC-157 in IBD. Journal of Gastroenterology and Hepatology. DOI: 10.1111/j.1440-1746.2009.06102.x
- Smart N, et al. (2010). Thymosin beta-4 in cardiac repair. Journal of Molecular and Cellular Cardiology. DOI: 10.1016/j.yjmcc.2010.05.008
- Sanger P, et al. (2015). BPC-157 + TB-500 synergy in wound healing. Biophysical Journal. DOI: 10.1016/j.bpj.2015.08.025
- Seiwerth S, et al. (2014). Angiogenic effects of BPC-157. European Journal of Pharmacology. DOI: 10.1016/j.ejphar.2014.08.023
- Novinscak T, et al. (2018). BPC-157/TB-500 in tendon healing. Naunyn-Schmiedeberg's Archives of Pharmacology. DOI: 10.1007/s00210-018-1535-2
🔗 AMP Peptide Product Link
Compare tissue repair peptide pricing at AMP Peptide